Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Oct;64(5):445-458.
doi: 10.1111/ajo.13820. Epub 2024 Jun 27.

Australasian recurrent pregnancy loss clinical management guideline 2024, part II

Adriana Suker  1 , Ying Li  2 , Danielle Robson  2 , Anthony Marren  2 ; Australasian CREI (Certificate of Reproductive Endocrinology and Infertility) Consensus Expert Panel on Trial Evidence (ACCEPT) Group
Collaborators, Affiliations
Practice Guideline

Australasian recurrent pregnancy loss clinical management guideline 2024, part II

Adriana Suker et al. Aust N Z J Obstet Gynaecol. 2024 Oct.

Abstract

Part II of the Australasian guideline for the investigation and management of recurrent pregnancy loss (RPL) provides evidence-based guidance on the management of RPL provided. The implications of inherited and acquired thrombophilia with respect to RPL and suggestions for clinical management are provided. Autoimmune factors, including human leukocyte antigen, cytokines, antinuclear antibodies and coeliac antibodies, and guidance for management are discussed. Infective, inflammatory and endometrial causes of RPL are discussed in detail. Environmental and lifestyle factors, male factor and unexplained causes are outlined. Levels of evidence and grades of consensus are provided for all evidence-based statements.

Keywords: RPL; guideline; recurrent miscarriage; recurrent pregnancy loss.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary for management of the male partner. BMI, body mass index; DFI, DNA fragmentation index.
See this image and copyright information in PMC

References

    1. Dizon‐Townson DMC, Sibai B, Spong CY et al. The relationship between the factor V leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106(3): 517–524. - PubMed
    1. Said JM, Higgins JR, Moses EK et al. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 2010; 115(1): 5–13. - PubMed
    1. Murphy RP, Donoghue C, Nallen RJ et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20(1): 266–270. - PubMed
    1. Clark P, Walker ID, Govan L et al. The GOAL study: A prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol 2008; 140(2): 236–240. - PubMed
    1. Linqvist PSP, Marsaal K, Grennert L et al. Activated protein C resistance (FV: Q506) and pregnancy. Thromb Haemost 1999; 81(4): 532–537. - PubMed

Publication types

LinkOut - more resources